Litwin A, Pesce A J, Michael J G
Department of Microbiology and Molecular Genetics, University of Cincinnati College of Medicine, Ohio.
Int Arch Allergy Appl Immunol. 1988;87(4):361-6. doi: 10.1159/000234701.
Nine patients with anaphylactic sensitivity to honey bee venom (HBV) were treated with P-1, a pepsin derived fragment of HBV phospholipase A2 (PLA2). P-1 caused only rare reactions with doses of 100 micrograms/injection. Treatment resulted in a substantial decrease in specific anti-PLA2 IgE and IgG antibodies as well as a decline in skin test sensitivity to PLA2. Another group of HBV-sensitive patients was treated with unaltered PLA2. Doses greater than 20 micrograms/injection were not tolerated. PLA2 injections caused an increase in anti-PLA2 IgG and IgE antibodies as well as increase in skin test sensitivity. This study demonstrates that a nonimmunogenic fragment derived from an allergen can downregulate immune responses and thus offer a new modality for therapy of allergic diseases.
九名对蜂毒(HBV)过敏的患者接受了P-1治疗,P-1是从HBV磷脂酶A2(PLA2)衍生的胃蛋白酶片段。P-1以100微克/注射的剂量仅引起罕见反应。治疗导致特异性抗PLA2 IgE和IgG抗体大幅减少,以及对PLA2皮肤试验敏感性下降。另一组HBV敏感患者接受未改变的PLA2治疗。大于20微克/注射的剂量无法耐受。PLA2注射导致抗PLA2 IgG和IgE抗体增加以及皮肤试验敏感性增加。这项研究表明,源自过敏原的非免疫原性片段可以下调免疫反应,从而为过敏性疾病的治疗提供一种新的方法。